慢性肾脏病肌肉萎缩机制的研究进展

doi:10.3969/j.issn.1671-4091.2021.10.002

中国血液净化 ›› 2021, Vol. 20 ›› Issue (10): 654-656.doi: 10.3969/j.issn.1671-4091.2021.10.002

• 专题与讲座·党为人民谋健康的100年 • 上一篇下一篇

慢性肾脏病肌肉萎缩机制的研究进展

赵立希¹,于艳¹,马迎春²

1中国康复科学所康复医学所，神经损伤与康复北京市重点实验室，北京脑重大疾病研究院神经损伤与修复研究所
2首都医科大学康复医学院，中国康复研究中心北京博爱医院肾内科

收稿日期:2021-05-06 修回日期:2021-05-29 出版日期:2021-10-12 发布日期:2021-10-12
通讯作者: 于艳 yuyancrrc@163.com E-mail:yuyancrrc@163.com
基金资助:
中央级公益性科研院所基本科研业务费专项资金(2019cz-10)

Advance in mechanism of muscular dystrophy in chronic kidney diseases

1 Institute of Rehabilitation Medicine, China Rehabilitation Science Institute, Beijing Key Laboratory of Neural Injury and Rehabilitation, Center of Neural Injury and Repair, Beijing Institute for Brain Disorders, Beijing 100068, China 2 Department of Nephrology, Beijing BoAi Hospital, China Rehabilitation Research

Received:2021-05-06 Revised:2021-05-29 Online:2021-10-12 Published:2021-10-12
Contact: yan 无yu E-mail:yuyancrrc@163.com

摘要/Abstract

摘要： 【摘要】肌肉萎缩是慢性肾脏病(chronic kidney disease，CKD)中后期常见的并发症，主要表现为肌肉质量减轻、肌肉力量降低、肌肉功能减退等。肌肉蛋白降解的增加是肌肉萎缩的主要原因，CKD 患者体内有毒代谢产物的累积、血浆pH 值的降低等病理状态能够激发肌肉的蛋白质降解途径从而导致肌肉萎缩。本文将从尿毒症毒素、代谢性酸中毒、炎症、激素和肠道菌群5 个方面对CKD 肌肉萎缩机制的研究进展进行综述。

关键词: 慢性肾脏病, 肌肉萎缩, 信号通路

Abstract: 【Abstract】Muscle atrophy is a common complication in the middle and late stage of chronic kidney disease (CKD), which mainly manifested as decreased muscle mass, decreased muscle strength, and decreased muscle function. The main cause of muscle atrophy is the enhancement of muscle protein degradation. The muscle protein degradation pathway can be stimulated by CKD pathological conditions such as the accumulation of toxic metabolites and the decrease of plasma pH value, then lead to muscle atrophy. This paper reviewed the research progress of muscle atrophy in CKD from the following five aspects: uremia toxin, metabolic acidosis, inflammation, hormones and intestinal flora.

Key words: Chronic kidney diseases, Muscular dystrophy, Signal pathway

中图分类号:

R692.5

赵立希, 于艳, 马迎春. 慢性肾脏病肌肉萎缩机制的研究进展[J]. 中国血液净化, 2021, 20(10): 654-656.

参考文献

[1] Sato E, Mori T, Mishima E, et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease [J]. Sci Rep, 2016, 6:36618.
[2] Enoki Y, Watanabe H, Arake R, et al. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1 [J]. Sci Rep, 2016, 6:32084.
[3] Enoki Y, Watanabe H, Arake R, et al. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction [J]. J Cachexia Sarcopenia Muscle, 2017, 8(5): 735-747.
[4] Vidoni ML, Pettee Gabriel K, Luo ST, et al. Relationship between Homocysteine and Muscle Strength Decline: The Baltimore Longitudinal Study of Aging [J]. J Gerontol A Biol Sci Med Sci, 2018, 73(4): 546-551.
[5] Majumder A, Singh M, Behera J, et al. Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury [J]. Am J Physiol Cell Physiol, 2018, 315(5): C609-C622.
[6] Veeranki S, Lominadze D, Tyagi SC. Hyperhomocysteinemia inhibits satellite cell regenerative capacity through p38 alpha/beta MAPK signaling [J]. Am J Physiol Heart Circ Physiol, 2015, 309(2): H325-334.
[7] Kraut J A, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management [J]. Nat Rev Nephrol, 2010, 6(5): 274-285.
[8] May R C, Kelly RA, Mitch WE. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism [J]. J Clin Invest, 1986, 77(2): 614-621.
[9] Sato AY, Richardson D, Cregor M, et al. Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases [J]. Endocrinology, 2017, 158(3): 664-677.
[10] Mutsvangwa T, Gilmore J, Squires JE, et al. Chronic metabolic acidosis increases mRNA levels for components of the ubiquitin-mediated proteolytic pathway in skeletal muscle of dairy cows [J]. J Nutr, 2004, 134(3): 558-561.
[11] Pickering WP, Baker FE, Brown J, et al. Glucocorticoid antagonist RU38486 fails to block acid-induced muscle wasting in vivo or in vitro [J]. Nephrol Dial Transplant, 2003, 18(8): 1475-1484.
[12] Evans K, Nasim Z, Brown J, et al. Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle [J]. J Am Soc Nephrol, 2008, 19(11): 2119-2129.
[13] Romanova Y, Laikov A, Markelova M, et al. Proteomic Analysis of Human Serum from Patients with Chronic Kidney Disease [J]. Biomolecules, 2020, 10(2):
[14] Verzola D, Bonanni A, Sofia A, et al. Toll-like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease [J]. J Cachexia Sarcopenia Muscle, 2017, 8(1): 131-144.
[15] Silva KA, Dong J, Dong Y, et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia [J]. J Biol Chem, 2015, 290(17): 11177-11187.
[16] Ma JF, Sanchez BJ, Hall DT, et al. STAT3 promotes IFNgamma/TNFalpha-induced muscle wasting in an NF-kappaB-dependent and IL-6-independent manner [J]. EMBO Mol Med, 2017, 9(5): 622-637.
[17] Zhang G, Liu Z, Ding H, et al. Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways [J]. Sci Rep, 2017, 7(1): 2273.
[18] Schulz A, Jankowski J, Zidek W, et al. Absolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS/MS [J]. Clin Proteomics, 2014, 11(1): 37.
[19] Du Bois P, Pablo Tortola C, Lodka D, et al. Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression [J]. Circ Res, 2015, 117(5): 424-436.
[20] Shen C, Zhou J, Wang X, et al. Angiotensin-II-induced Muscle Wasting is Mediated by 25-Hydroxycholesterol via GSK3beta Signaling Pathway [J]. EBioMedicine, 2017, 16(238-250.
[21] Liu Y, Bi X, Zhang Y, et al. Mitochondrial dysfunction/NLRP3 inflammasome axis contributes to angiotensin II-induced skeletal muscle wasting via PPAR-gamma [J]. Lab Invest, 2020, 100(5): 712-726.
[22] Ros S, Carrero JJ. Endocrine alterations and cardiovascular risk in CKD: is there a link? [J]. Nefrologia, 2013, 33(2): 181-187.
[23] Cigarran S, Pousa M, Castro MJ, et al. Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease [J]. J Ren Nutr, 2013, 23(5): e89-95.
[24] Chiang J M, Kaysen GA, Segal M, et al. Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis [J]. Nephrol Dial Transplant, 2019, 34(5): 802-810.
[25] Dalbo VJ, Roberts MD, Mobley CB, et al. Testosterone and trenbolone enanthate increase mature myostatin protein expression despite increasing skeletal muscle hypertrophy and satellite cell number in rodent muscle [J]. Andrologia, 2017, 49(3):
[26] Ghanim H, Dhindsa S, Batra M, et al. Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth [J]. J Clin Endocrinol Metab, 2019, 104(6): 2094-2102.
[27] Pronsato L, Milanesi L, Vasconsuelo A, et al. Testosterone modulates FoxO3a and p53-related genes to protect C2C12 skeletal muscle cells against apoptosis [J]. Steroids, 2017, 124(35-45.
[28] Schaefer F, Veldhuis JD, Stanhope R, et al. Alterations in growth hormone secretion and clearance in peripubertal boys with chronic renal failure and after renal transplantation. Cooperative Study Group of Pubertal development in Chronic Renal Failure [J]. J Clin Endocrinol Metab, 1994, 78(6): 1298-1306.
[29] Krieg RJ, Jr., Veldhuis JD, Thornhill BA, et al. Growth hormone (GH) secretion, GH-dependent gene expression, and sexually dimorphic body growth in young rats with chronic renal failure [J]. Endocrine, 2008, 33(3): 323-330.
[30] Janjua HS, Mahan JD. Growth in chronic kidney disease [J]. Adv Chronic Kidney Dis, 2011, 18(5): 324-331.
[31] Greenstein J, Guest S, Tan J C, et al. Circulating growth hormone binding protein levels and mononuclear cell growth hormone receptor expression in uremia [J]. J Ren Nutr, 2006, 16(2): 141-149.
[32] Sun DF, Zheng Z, Tummala P, et al. Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle [J]. J Am Soc Nephrol, 2004, 15(10): 2630-2636.
[33] Mak RH, Cheung WW, Roberts CT, Jr. The growth hormone-insulin-like growth factor-I axis in chronic kidney disease [J]. Growth Horm IGF Res, 2008, 18(1): 17-25.
[34] Han DS, Chen YM, Lin SY, et al. Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis [J]. Clin Endocrinol (Oxf), 2011, 75(6): 857-863.
[35] Lun H, Yang W, Zhao S, et al. Altered gut microbiota and microbial biomarkers associated with chronic kidney disease [J]. Microbiologyopen, 2019, 8(4): e00678.
[36] Li F, Wang M, Wang J, et al. Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease [J]. Front Cell Infect Microbiol, 2019, 9(206.
[37] Kikuchi M, Ueno M, Itoh Y, et al. Uremic Toxin-Producing Gut Microbiota in Rats with Chronic Kidney Disease [J]. Nephron, 2017, 135(1): 51-60.
[38] Liu Y, Li J, Yu J, et al. Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change [J]. J Pharm Biomed Anal, 2018, 149(425-435.
[39] de Sire R, Rizzatti G, Ingravalle F, et al. Skeletal muscle-gut axis: emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases [J]. Minerva Gastroenterol Dietol, 2018, 64(4): 351-362.
[40] Lahiri S, Kim H, Garcia-Perez I, et al. The gut microbiota influences skeletal muscle mass and function in mice [J]. Sci Transl Med, 2019, 11(502):
[41] Nay K, Jollet M, Goustard B, et al. Gut bacteria are critical for optimal muscle function: a potential link with glucose homeostasis [J]. Am J Physiol Endocrinol Metab, 2019, 317(1): E158-E171.
[42] Hu L, Klein J D, Hassounah F, et al. Low-frequency electrical stimulation attenuates muscle atrophy in CKD--a potential treatment strategy [J]. J Am Soc Nephrol, 2015, 26(3): 626-635.
[43] Moinuddin I, Leehey DJ. A comparison of aerobic exercise and resistance training in patients with and without chronic kidney disease [J]. Adv Chronic Kidney Dis, 2008, 15(1): 83-96.
dv Chronic Kidney Dis, 2008, 15(1): 83-96.

慢性肾脏病肌肉萎缩机制的研究进展

Advance in mechanism of muscular dystrophy in chronic kidney diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

[1]	冯佳楠, 祖源, 路香雪, 李寒, 王世相. 蛋白结合毒素清除方式的研究进展[J]. 中国血液净化, 2022, 21(02): 77-80.
[2]	张帆, 王蔚琼, 张华春. 慢性肾脏病的运动康复临床实践指南及专家共识解读[J]. 中国血液净化, 2022, 21(02): 111-114.
[3]	张昭昕, 李守琴, 虎洁婷, 何雄, 杨娟, 张修斌. 慢性肾脏病患者衰弱发生率的Meta分析[J]. 中国血液净化, 2022, 21(02): 140-144.
[4]	傅晓岑, 任红, 陈楠. 肾性贫血的治疗研究[J]. 中国血液净化, 2022, 21(01): 6-9.
[5]	彭红梅, 石钰, 邓俊娜, 蒲诗, 黄霞, 李杨. 手术前握力锻炼对拟行动静脉内瘘术的慢性肾脏病患者前臂血管影响的Meta分析[J]. 中国血液净化, 2021, 20(10): 696-701.
[6]	赵东方, 戎殳. B 型利钠肽/N 末端B 型利钠肽原在慢性肾脏病中的研究进展[J]. 中国血液净化, 2021, 20(07): 437-440.
[7]	史书君, 王文革, 梁耀军. 非透析慢性肾脏病患者的多学科医疗管理效果探讨[J]. 中国血液净化, 2021, 20(02): 82-85.
[8]	赵亚, 王俭勤. H 型高血压在慢性肾脏病中的研究进展[J]. 中国血液净化, 2020, 19(11): 768-771.
[9]	马金兰, 孙雪, 张志强, 王燕, 梅峰. 转化生长因子-RhoGTP 酶／Rho 激酶系统信号通路在低氧诱导大鼠肾小球内皮细胞-间充质细胞转分化中的作用及机制研究[J]. 中国血液净化, 2020, 19(10): 683-687.
[10]	李赞, 周树录. 维生素D 受体TaqI 基因多态性与慢性肾脏病透析患者预后的关系[J]. 中国血液净化, 2020, 19(06): 372-375.
[11]	陈吉林, 林洪丽. 慢性肾脏病患者铁缺乏及铁代谢[J]. 中国血液净化, 2020, 19(06): 368-371.
[12]	蒋易, 陆晓青, 梁献慧, 乔颖进, 王沛. 基层血液透析患者骨与矿物质代谢现状调查[J]. 中国血液净化, 2020, 19(04): 225-229.
[13]	蒲蕾, 王莉. 红细胞生成刺激因子低反应的原因分析及处理策略[J]. 中国血液净化, 2020, 19(03): 153-156.
[14]	潘林蓉, 刘爽, 蒋更如. 慢性肾脏病患者生活质量评估方法与影响因素的研究现状[J]. 中国血液净化, 2020, 19(01): 49-51.